Previous clinical trials have shown a clinical benefit of the addition of MET in NSCLC patients undergoing immunotherapy [29, 30], but the small sample sizes and lack of evaluation of LKB1 mutations may have limited their conclusions. Here, MET is linked to non-small cell lung carcinoma.